2016 Section 5 Green Book

Mener and Lin

61. Abramson MJ, Puy RM, Weiner JM. Injection aller- gen immunotherapy for asthma. Cochrane Database Syst Rev . 2010;(8):CD001186. 62. Johnstone DE, Dutton A. The value of hyposensiti- zation therapy for bronchial asthma in children—a 14-year study. Pediatrics . 1968;42:793–802. 63. Niggemann B, Jacobsen L, Dreborg S, et al. Five-year follow-up on the PAT study: specific immunotherapy and long-term prevention of asthma in children. Al- lergy . 2006;61:855–859. 64. Olaguibel JM, Alvarez Puebla MJ. Efficacy of sub- lingual allergen vaccination for respiratory allergy in children. Conclusions from one meta-analysis. J In- vestig Allergol Clin Immunol . 2005;15:9–16. 65. Milani M, Pecora S, Burastero S. Observational study of sublingual specific immunotherapy in persistent and intermittent allergic rhinitis: the EFESO trial. Curr Med Res Opin . 2008;24:2179–2724. 66. Lin SY, Erekosima N, Kim JM, et al. Sublingual im- munotherapy for the treatment of allergic rhinocon- junctivitis and asthma: a systematic review. JAMA . 2013;309:1278–1288. 67. Shekelle PG, Woolf SH, Eccles M, Grimshaw J. Clinical guidelines: developing guidelines. BMJ . 1999;318:593–596. 68. Passalacqua G, Durham SR. Allergic rhinitis and its impact on asthma update: allergen immunotherapy. J Allergy Clin Immunol . 2007;119:881–891. 69. Penagos M, Passalacqua G, Compalati E, et al. Meta- analysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric pa- tients, 3–18 years of age. Chest . 2008;133:599–609. 70. Compalati E, Passalacqua G, Bonini M, Canon- ica GW. The efficacy of sublingual immunotherapy for house dust mites respiratory allergy: results of a GA2LEN meta-analysis. Allergy . 2009;64:1570– 1579. 71. Basomba A, Tabar AI, de Rojas DH, et al. Aller- gen vaccination with a liposome-encapsulated extract of Dermatophagoides pteronyssinus : a randomized, double-blind, placebo-controlled trial in asthmatic pa- tients. J Allergy Clin Immunol . 2002;109:943–948. 72. Pifferi M, Baldini G, Marazzini G, et al. Benefits of im- munotherapy with a standardized Dermatophagoides pteronyssinus extract in asthmatic children: a three- year prospective study. Allergy . 2002;57:785–790. 73. Garcia-Robaina JC, Sanchez I, de la Torre F, Fernandez-Caldas E, Casanovas M. Successful man- agement of mite-allergic asthma with modified extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae in a double blind, placebo-controlled study. J Allergy Clin Immunol . 2006;118:1026–1032. 74. Tabar AI, Echechipia S, Garcia BE, et al. Double-blind comparative study of cluster and conventional immunotherapy schedules with Der- matophagoides pteronyssinus . J Allergy Clin Im- munol . 2005;116:109–118. 75. Keles S, Karakoc-Aydiner E, Ozen A, et al. A novel ap- proach in allergen-specific immunotherapy: combina- tion of sublingual and subcutaneous routes. J Allergy Clin Immunol . 2011;128:808–815. 76. Bahceciler NN, Arikan C, Taylor A, et al. Impact of sublingual immunotherapy on specific antibody levels in asthmatic children allergic to house dust mites. Int Arch Allergy Immunol . 2005;136:287–294. 77. Roberts G, Hurley C, Turcanu V, Lack G. Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma. J Allergy Clin Immunol . 2006;117:263–268. 78. Marogna M, Braidi C, Bruno ME, et al. The contribu- tion of sublingual immunotherapy to the achievement of control in birch-related mild persistent asthma: a real life randomized trial. Allergol Immunopathol (Madr) . 2013;41:216–224. 79. Jacobsen L, Nuchel PB, Wihl JA, et al. Immunotherapy with partially purified and standardized tree pollen extracts. Results from long term (6-year) follow-up. Allergy . 1997;52:914–920. 80. Novembre E, Galli E, Landi F, et al. Coseasonal sub- lingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol . 2004;114:851–857. 81. Pajno GB, Vita D, Parmiani S, Caminiti L, La Grutta S, Barberio G. Impact of sublingual immunotherapy on seasonal asthma and skin reactivity in children aller- gic to Parietaria pollen treated with inhaled fluticasone propionate. Clin Exp Allergy . 2003;33:1641–1647. 82. Georgopoulos R, Krouse JH, Toskala E. Why oto- laryngologists and asthma are a good match: the al- lergic rhinitis-asthma connection. Otolaryngol Clin North Am . 2014;47:1–12.

40. Reicin A, White R, Weinstein SF, et al. Montelukast, a leukotriene receptor antagonist in combination with loratadine, a histamine receptor antagonist, in the treatment of chronic asthma. Arch Intern Med . 2000;160:2481–2488. 41. Weiner JM, Abramson MJ, Puy RM. Intranasal cor- ticosteroids versus oral H1 receptor antagonists in al- lergic rhinitis: systematic review of randomized con- trolled trials. BMJ . 1998;317:1624–1629. 42. Foresi A, Pelucchi A, Gherson G, Mastropasqua B, Chiapparino A. Once daily intranasal fluticasone pro- pionate (200 μ g) reduces nasal symptoms and inflam- mation but also attenuates the increase in bronchial responsiveness during the pollen season in aller- gic rhinitis. J Allergy Clin Immunol . 1996;98:274– 282. 43. Whicker JH, Kern EB. The nasopulmonary reflex in the awake animal. Ann Otol . 1973;82:355–358. 44. Mastruzzo C, Greco LB, Nakano K, et al. Impact of intranasal budesonide on immune inflammatory responses and epithelial remodeling in chronic up- per airway inflammation. J Allergy Clin Immunol . 2003;112:37–44. 45. Welsh PW, Stricker WE, Chu CP, et al. Efficacy of beclomethasone nasal solution, flunisolide, and cro- molyn in relieving symptoms of ragweed allergy. Mayo Clin Proc . 1987;62:125–134. 46. Henrickson JM, Wenzel A. Effect of an intranasally administered corticosteroid (budesonide) on nasal ob- struction, mouth breathing, and asthma. Am Rev Respir Dis . 1984;130:1014–1018. 47. Watson WT, Becker AB, Simons FE. Treatment of allergic rhinitis with intranasal corticosteroids in pa- tients with mild asthma: effect on lower airway re- sponsiveness. J Allergy Clin Immunol . 1993;91:97– 101. 48. Corren J, Adinoff AD, Buchmeier AD, Irvin CG. Nasal beclomethasone prevents the seasonal increase in bronchial responsiveness in patients with aller- gic rhinitis and asthma. J Allergy Clin Immunol . 1992;90:250–256. 49. Wilson AM, Orr LC, Sims EJ, Dempsey OJ, Lipworth BJ. Antiasthmatic effects of mediator blockade versus topical corticosteroids in allergic rhinitis and asthma. Am J Respir Crit Care Med . 2000;162:1297–1301. 50. Baiardini I, Villa E, Rogkakou A, et al. Effects of mometasone furoate on the quality of life: a ran- domized placebo-controlled trial in persistent allergic rhinitis and intermittent asthma using the Rhinasthma questionnaire. Clin Exp Allergy . 2010;41:417–423. 51. Wood RA, Egglesston PA. The effects of intranasal steroids on nasal and pulmonary responses to cat ex- posure. Am J Respir Crit Care Med . 1995;151:315– 320. 52. Gani F, Pozzi E, Crivellaro MA, et al. The role of patient training in the management of seasonal rhinitis and asthma: clinical implications. Allergy . 2001;56:65–68. 53. Crystal-Peters J, Neslusan C, Crown WH, Torres A. Treating allergic rhinitis in patients with comorbid asthma: the risk of asthma-related hospitalization and emergency department visits. J Allergy Clin Immunol . 2002;109:57–62. 54. Adams RJ, Fuhlbrigge AL, Finkelstein JA, Weiss ST. Intranasal steroids and the risk of emergency de- partment visits for asthma. J Allergy Clin Immunol . 2002;109:636–642. 55. Moller C, Dreborg S, Ferdousi HA, et al. Pollen im- munotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT- study). J Allergy Clin Immunol . 2002;109:251–256. 56. Mener DJ, Shargorodsky J, Varadhan R, Lin SY. Top- ical intranasal corticosteroids and growth velocity in children: a meta-analysis. Int Forum Allergy Rhinol . 2015;5:95–103. 57. Akdis CA. Therapies for allergic inflammation: re- fining strategies to induce tolerance. Nat Med . 2012;18:736–749. 58. Benjaponpitak S, Oro A, Maguire P, et al. The kinetics of change in cytokine production by CD4 T cells dur- ing conventional allergen immunotherapy. J Allergy Clin Immunol . 1999;103:468–475. 59. Polosa R, Gotti FL, Mangano G, et al. Effect of immunotherapy on asthma progression, BHR and sputum eosinophils in allergic rhinitis. Allergy . 2004;59:1224–1228. 60. Ross RN, Nelson HS, Finegold I. Effectiveness of specific immunotherapy in the treatment of asthma: a meta-analysis of prospective, randomized, double-blind, placebo controlled studies. Clin Ther . 2000;22:329–341.

17. Simons FER. Is antihistamine (H1-receptor antago- nist) therapy useful in clinical asthma? Clin Exp Al- lergy . 1999;29(Suppl 3):98–104. 18. Platts-Mills TA, Wheatley LM. The role of allergy and atopy in asthma. Curr Opin Pulm Med. 1996;2:29– 34. 19. Adinoff AD, Irbin CG. Upper respiratory tract disease and asthma. Semin Respir Med . 1987;8:308–314. 20. Bardin PG, Van Heerden BB, Joubert JR. Absence of pulmonary aspiration of sinus contents in patients with asthma and sinusitis. J Allergy Clin Immunol . 1990;86:82–88. 21. Calamita Z, Saconato H, Pela AB, et al. efficacy of sublingual immunotherapy in asthma: systematic re- view of randomized clinical trials using the Cochrane collaboration method. Allergy . 2006;61:1162–1172. 22. Pichler CE, Helbing A, Pichler WJ. Three years of spe- cific immunotherapy with house-dust-mite extracts in patients with rhinitis and asthma: significant improve- ment of allergen-specific parameters and of nonspecific bronchial hyperreactivity. Allergy . 2001;56:301–306. 23. Erbas B, Akram M, Dharmage SC, et al. The role of seasonal grass pollen on childhood asthma emer- gency department presentations. Clin Exp Allergy . 2011;42:799–805. 24. Borade PS, Ballary CC, Currie GP, Lee DKC. Mod- ern H1-antihistamines in asthma. Drug Discov Today Ther Strateg . 2006;3:253–259. 25. Aaronson DW. Evaluation of cetirizine in patients with allergic rhinitis and perennial asthma. Ann Al- lergy Asthma Immunol . 1996;76:440–446. 26. Fadel R, Herpin-Richard N, Rihoux JP, Henocq E. Inhibitory effect of cetirizine 2HCL on eosinophil mi- gration in vivo. Clin Allergy . 1987;17:373–379. 27. Tashkin DP, Brik A, Gong H Jr. Cetirizine inhi- bition of histamine-induced bronchospasm. Ann Al- lergy . 1987;59:49–52. 28. Woosley RL, Chen Y, Freiman JP, Giillis RA. Mecha- nism of the cardiotoxic actions of Terfenadine. JAMA . 1993;269:1532–1536. 29. Dijkman JH, Hekking PRM, Molkenboer JF, Vander- schueren R, Bernheim J, Van Ganse EH. Prophylactic treatment of grass pollen-induced asthma with ceti- rizine. Clin Exp Allergy . 1990;20:483–490. 30. Spector SL, Nicodemus CF, Corren J, et al. Com- parison of the bronchodilatory effects of cetirizine, albuterol, and both together versus placebo in pa- tients with mild-to-moderate asthma. J Allergy Clin Immunol . 1995;96:174–181. 31. Grant JA, Nicodemus CF, Findlay SR, et al. Cetirizine in patients with seasonal rhinitis and concomitant asthma: prospective, randomized placebo-controlled trial. J Allergy Clin Immunol . 1995;95:923–932. 32. ETAC Study Group. Allergic factors associated with the development of asthma and the influence of cetirizine in a double-blind, randomised, placebo- controlled trial: first results of ETAC. Early Treat- ment of the Atopic Child. Pediatr Allergy Immunol. 1998;9:116–124. 33. Corren J, Harris A, Aaronson D, et al. Efficacy and safety of loratadine plus pseudoephedrine in patients with seasonal allergic rhinitis and mild asthma. J Al- lergy Clin Immunol . 1997;100:781–788. 34. Berger WE, Schenkel EJ, Mansfield LE; Desloratadine Study Group. Safety and efficacy of desloratadine 5 mg in asthma patients with seasonal allergic rhinitis and nasal congestion. Ann Allergy Asthma Immunol . 2002;89:485–491. 35. Baena-Cagnani CE, Berger WE, Du Buaske LM, et al. Comparative effects of desloratadine versus mon- telukast on asthma symptoms and use of B2-agonists in patients with seasonal allergic rhinitis and asthma. Int Arch Allergy Immunol . 2003;130:307–313. 36. Reinartz SM, Overbeek SE, Kleinjan A, et al. Deslo- ratadine reduces systemic allergic inflammation fol- lowing nasal provocation in allergic rhinitis and asthma patients. Allergy . 2005;60:1301–1307. 37. Lu S, Liu N, Dass B, Reiss TF. A randomized study comparing the effect of loratadine added to montelukast with montelukast, loratadine, and be- clomethasone monotherapies in patients with chronic asthma. J Asthma . 2009;46:465–469. 38. Schenkel EJ, Berger WE. Treatment of allergic rhinitis with intranasal steroids and their effects on the lower airway. Pediatr Ann . 2000;29:422–424. 39. Nishimura M, Koga T, Kamimura T, Sato R, et al. Comparison of leukotriene receptor antagonists and anti-histamines as an add-on therapy in patients with asthma complicated by allergic rhinitis. Kurume Med J . 2011;58:9–14.

International Forum of Allergy & Rhinology, Vol. 5, No. S1, September 2015

207